drugset / Trial / NCT05912218
REducing Diabetic MacrovascUlar Complications DuE to Peripheral Arterial Disease- REDUCE-PAD
Phase 2
Active not recruiting
70 enrolled
National Heart Centre Singapore
Khoo Teck Puat Hospital · collabNational University Health System, Singapore · collabSingapore General Hospital · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Phase IIa, multi-centre study conducted at 3 sites in Singapore (SGH and NUHS, KTPH). 70 patients with diabetes mellitus (DM) and peripheral arterial disease (PAD) will be randomised in a ratio 1:1 to receive normal saline control or MEDI6570 400mg by monthly subcutaneous injection for 9 months.
Timeline
- Start
- 2023-11-02
- Primary completion
- 2025-09-01
- Completion
- 2025-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GOLOCDACIMAB | Monoclonal antibody | 400 mg | Subcutaneous |